Physician profile
Scott Jon Beougher
NPI 1063421683
$3,701.02
in general payments reported to CMS, 2019-2025
33 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $345 · 2021: $507 · 2022: $658 · 2023: $779 · 2024: $633 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,034.49 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $530.77 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $370.70 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.86 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $175.24 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $152.37 | 2019-2025 | |
| Lilly USA, LLC | $143.61 | 2021-2024 | Mounjaro, Zepbound |
| Ethicon INC. | $130.59 | 2023 | Monarch Platform |
| Astellas Pharma US INC | $127.71 | 2023-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $81.85 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.54 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $78.41 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.23 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $65.44 | 2021-2022 | |
| Amgen INC. | $55.32 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $49.32 | 2019-2022 | |
| Exact Sciences Corporation | $48.18 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.52 | 2022-2024 | Trulance, Xifaxan |
| Lifescan, INC. | $32.35 | 2023 | |
| Dexcom, INC. | $26.23 | 2023 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $19.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.23 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.87 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.42 | 2021 | |
| Hikma Pharmaceuticals USA | $16.72 | 2019 | |
| Adlon Therapeutics L.P. | $15.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.95 | 2023 | Ajovy |
| Exeltis, USA INC. | $14.64 | 2024 | Slynd |
| Shire North American Group INC | $14.20 | 2019 | |
| Clarus Therapeutics INC. | $14.07 | 2021 | |
| Gilead Sciences, INC. | $13.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Beougher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.